Product Details
VOGLIBOSE 0.3 MG
Introduction : Type 2 diabetes mellitus (T2DM) is currently at epidemic proportions and the forecast is for a continued sharp increase in global prevalence. An even larger proportion of the population has prediabetes (impaired glucose tolerance [IGT]) underscoring the urgent need for preventive strategies. Even in the presence of adequate glycosylated hemoglobin (HbA1c) levels, postprandial hyperglycemia can occur and is known to have a stronger association with cardiovascular morbidity than fasting glucose. The ?-glucosidase inhibitor voglibose is widely used to improve postprandial hyperglycemia.
Indication : Voglibose 0.3mg is indicated For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
Storage : Direct contact with heat, air and light may damage the quality medicines. The medicine must be kept in a safe place and out of children?s reach. Mainly the drug should be kept at room temperature between (20?C and 25?C).
Side Effects : Some of the common side effects of Voglibose are:
Diarrhea, Flatulence, Pneumatosis Intestinalis, Abnormal Liver Function, Nausea, Vomiting, Dizziness , Abdominal pain, Skin rash
The common side effects don?t need any medical attention and will disappear as your body gets adjusted to the dosage. But if you are facing any kind of serious or rare side effects then immediately seek medical attention.
References : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919386/
Efficacy of voglibose in type 2 diabetes
Mechanism of Action : Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level.